Topics & People

A major pharmaceutical company mentioned in the context of a large licensing deal with Chinese company 3S Bio.

An FDA approval for a CRISPR-based gene-editing therapy to treat Sickle Cell Anemia, highlighted by Chamath Palihapitiya as a major science breakthrough in 2023.

A term used to describe companies and movements that adopt progressive social stances, identified as a 'biggest loser in business' for facing consumer backlash and revenue loss.

The traditional index of the top seven highly valued public tech companies.

The October 7th attack, cited as the biggest political surprise of 2023 by David Sachs, which shifted the political paradigm in the Middle East and American politics.

President of Ukraine, chosen by David Sachs as the biggest political loser of 2023, citing a shift in media perception and a failed gamble to pressure Putin instead of making peace.

A social and corporate movement focused on diversity, equity, and inclusion, named the biggest political loser of 2023 due to negative public perception and its linkage to anti-Semitism.

An intergovernmental organization originally comprising Brazil, Russia, India, China, and South Africa that has expanded to include new members to challenge Western unipolarity.

An anticipated trend for 2024 where predictive AI models will accelerate the discovery of new molecules, materials, and production methods in fields like biopharma and chemical engineering.

Startups focused on creating large language models. Predicted by Jason Calacanis to be the worst-performing asset class in 2024 due to overvaluation, intense competition, and the rapid progress of open-source alternatives.

Shares of companies in the energy sector, predicted by David Sachs to be a top-performing asset in 2024 due to the high risk of escalating geopolitical conflicts.

A predicted market trend where the valuations of public tech companies will outperform late-stage private tech companies, which are expected to face a valuation reset.